Assay Development

Imaging the Future of Therapeutics

Accelerating your Assay Program

BioLaurus is a leader in the development of novel imaging assays and the adaptation of clinical imaging procedures to the preclinical research space. This talent derives not from the individual instruments (PET, Optical, CT), but in the knowledge and expertise that surrounds our vast competencies and allows us to provide you with assay solutions. Bringing you results, faster.


Examples of Innovation in Assay Development

Development of your assays are an essential part of your product development lifecycle. Let us help you get there – faster and with more innovation. We can get your results. Take a look at some of our past successes:

Novel Enterocyte GI Contrast Agent

BioLaurus developed novel CT contrast agent to track in vivo lipid absorption in small intestine. Enterocytes as the critical functional cell of the intestines for nutrient absorption are on the front line for adverse effects of orally administered therapeutics.

The absorption of proteins, lipids, carbohydrates, and other nutrients is quite complex and perhaps the most complex mechanisms surround lipid absorption, remodeling, and transport. BioLaurus’ scientists could measure the rates of lipid absorption and rates of secretion in vivo. This work continues with the development of a proprietary contrast agent targeting the chylomicron pathway. This project involved the close collaboration of the Sponsor research team including pathologists and toxicologists with the BioLaurus team.

Platelet Survival and Sequestration

A number of therapeutics in a range of drug classes from small molecules to  biologics can have adverse effects on platelets (PLT) and therefore hemostasis. Imaging analysis can shed light on drug mechanism of action by tracking in-vivo over days PLT survival times and tissue sequestration. While such studies can be done in a variety of species, each has its own set of requirements in handling PLT. 

Working with a big biotech the BioLaurus team developed protocols for the In-111 labeling and in-vivo gamma camera imaging of NHP autologous platelets for survival and sequestration analysis. We developed techniques to successfully isolate and radiolabel NHP platelets without activation, something several major CRO were not able to do. Much of the imaging work has entailed the adaptation of clinical protocols for animal research – reverse translation. The resulting data will now be used to inform the ongoing clinical trials and be as translational as possible.

Blood-Brain Barrier Assays

The highly selective blood brain barrier (BBB) means that many small molecules, antisence oligonucleotides (ASO), and peptides cannot pass the BBB or do so at a moderate to slow rate. BBB permeability and knowledge of the mechanism; lipophilic permeability or receptor mediated can have a major impact on the PK profile of a brain targeting therapeutic. Equally important is the evaluation of target (neuron or glial) receptor kinetics.

Receptor mediated kinetics can be visualized and quantitated in normal animals as well as in models of oncology, Parkinson’s’, Alzheimer’s’, and neuroinflammatory models.

Neuro imaging studies are typically carried out as PET or SPECT studies with CT anatomic imaging. Where required we have the capability to develop C-11 and F-18 tracers.

In addition to imaging BBB studies BioLaurus has conducted traditional BBB studies with H-3 or C-14 labeled compounds. 

Have some spare time? It will be worth it.